Cytospector: what we do best!
Cytospector offers standardized and customized neuron-based high-content assays for compound screening and target identification (e.g. genetic screens) in the field of neurological and psychiatric disease. We use rodent primary neurons and human induced pluripotent stem (iPS) cell-derived neurons, which ideally represent neural processes and disease mechanisms, and have a unique expertise in monitoring disease-relevant changes in synapse formation, morphology, and synaptic transmission.
Cytospector expertise
Cytospector’s experimental set-up allows for large scale, highly sensitive and reproducible enhancer suppressor or compound screens for a range of CNS relevant phenotypes. Our fully automated cell culture integrated with automated imaging analysis has been validated in a number of screens for neurodegenerative diseases as well as neurotoxicity.
- Rodent primary neurons and human iPS cell-derived neurons
- Detailed analysis of synaptic phenotypes
- High-content microscopy
- High-content analysis of synaptic transmission
High-content assays
Neuron-based high-content assays for compound and genetic screens Using primary rodent neurons and human iPS cell-derived neurons, Cytospector provides high-content, high-throughput cellular screens for a variety of cellular and synaptic phenotypes that are relevant for neurological and psychiatric diseases. Cytospector offers the following assays:
- Standardized phenotypic assay for neuronal and synaptic morphology and function
- Alzheimer’s disease assay
- Schizophrenia assay
Assay development
On demand, Cytospector develops neuron-based high-content assays for compound screens and screens for therapeutic targets in the field of neurological and psychiatric disease.
Combination of advanced neuronal cell models, standardized analysis of a large number of relevant neuronal and synaptic phenotypes, and our long-standing expertise with high-content screening ensures optimal assay development.
Contact us with any questions or requests for assay development.
Contact